PubRank

William C Dougall

Author PubWeight™ 39.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010 3.66
2 Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009 2.51
3 Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 2012 2.07
4 RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 2012 1.98
5 A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 2002 1.54
6 Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther 2010 1.53
7 RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol Cell Biol 2006 1.49
8 RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 2008 1.42
9 Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2007 1.42
10 Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 2004 1.30
11 Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 2007 1.28
12 Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res 2006 1.18
13 Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Bone 2008 1.18
14 In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 2002 1.17
15 RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008 1.13
16 Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res 2003 1.10
17 RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2007 1.08
18 The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res 2005 1.04
19 RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat 2014 0.93
20 RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis 2013 0.91
21 RANKL inhibition: from mice to men (and women). Adv Exp Med Biol 2007 0.90
22 Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol 2007 0.87
23 Progestin effects on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res 2013 0.87
24 Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells 2013 0.85
25 Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 2010 0.84
26 RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat 2012 0.83
27 Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. Clin Exp Metastasis 2006 0.83
28 The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Ann N Y Acad Sci 2012 0.82
29 RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase. Breast Cancer Res Treat 2014 0.82
30 RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res 2015 0.81
31 RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. J Thorac Oncol 2014 0.81
32 Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion. Bone 2010 0.80
33 Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method. Appl Immunohistochem Mol Morphol 2017 0.75